TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration- Time Curve (AUC Last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of diarrhea, dysentery, and fever
Endpoint domain: Adverse events/effects
Primary endpoint: Serum IgA and IgG anti-S. flexneri 2a LPS antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiologic change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the Open Label Use of the Dapivirine Vaginal Matrix Ring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of MR protocol in diagnosing HCC and liver lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein carbonyls levels changes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Malondialdehyde levels changes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of normal esophageal transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with grade 3 or higher acute urinary and/or bowel toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Progressive disease requiring change of therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of decayed, missing and filled teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Mean number of decayed, missing and filled teeth surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change of mean number of decayed, missing and filled teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change of mean number of decayed, missing and filled teeth surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Level of cardiac biomarkers in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With Valid Recanalization Assessed by Magnetic Resonance Angiography (MRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of Patients With a Modified Rankin Scale (mRS) Score of 0-1 at 3 Months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum ischemia-modified albumin (IMA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormone therapy usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage change in urinary oxalate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Capillary blood glucose change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal muscle oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective symptom survey result
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heart failure requiring admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Mobility as Measured by the Timed Up & Go (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in IPSG (MRI) score for primary knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvements in physical disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cellular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HbA1c Change From Baseline to Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in skin microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in antimicrobial peptide composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antrum biopsy diagnostic performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in post-operative left ventricular functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Prosthetic mitral valve functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with Signs of left ventricular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Positive Urine Culture
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration curve (AUC0-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oropharyngeal sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (AEs) for all study participants
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of vital signs for all study participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Dose Limiting Toxicity (DLT) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Experiencing Potential Efficacy of ALT 803
Endpoint domain: Physiological/clinical
Primary endpoint: Preference between treatment alternatives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Treatment-emergent AEs (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulated GAS T score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of antibodies for dengue, chikungunya, and zika
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seric concentrations associated with maximum therapeutic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase insulin response measured as incremental area under the curve from 0-10 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Phase insulin response measured as incremental area under the curve from 10-45 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in composite score of vaginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VMI (Vaginal Maturation Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity assessed by The Faces Pain Scale -Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity assessed by the Non-Communicating Children's Pain Checklist-Revised (NCCPC-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from MAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to stable permanence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Positive parenting behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tumor Response (Complete Response or Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cohen's Kappa Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of standard motorcycle child safety helmet usage
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from baseline in faecal microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of complication needing re-hospitalisation or reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: Anticatabolic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence or absence of intracranial hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax of Faldaprevir (BI 201335)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) of Faldaprevir (BI 201335) From 0 to 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Deleobuvir (BI 207127)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of CBHP on depressive symptoms (PHQ-9 scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline Fugl Meyer Assessment Scale (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of chemotherapy courses completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Left Ventricular Ejection Fraction by Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Left Ventricular Ejection Fraction as Measured by Magnetic Resonance Imaging (MRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self Report of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain Threshold of the Masseter Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoral Muscle Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of CTCAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced death or dependency
Endpoint domain: Mortality/survival
Primary endpoint: Range of Motion (ROM) Lumbar Spine (Flexion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate and extent of absorption of hydrocodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipoproteins in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fatty acids in EDTA-Plasma and erythrocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to therapy on MRI or CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in CD4 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL, HDL, Cholesterol, Triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Spatiotemporal dynamic changes measured with electroencephalography (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral performance measured with Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Change in Brachial-femoral Pulse Wave Velocity (bfPWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Heart-middle Cerebral Artery Pulse Wave Velocity (Brain PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of child contacts placed on IPT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in HbA1C from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % variation in the pelvic incidence angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression - Improvement (CGI-I) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood oxygenation level dependent signal (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of verbal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of eyelash reflex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of anti-hepatitis B antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days Lost Due to Unplanned Cardiovascular Hospitalizations or Death of Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of subclinical vitamin D deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post operative pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in ECGs and vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lin concordance coefficient for fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lin concordance coefficient for lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS-%CV for total fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMS-%CV for total lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Evogliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced an HES Flare
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Withdrew From the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in 24-hour Average Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response - Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission - Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response - Maintenance Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission - Maintenance Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Montgomery-Åsberg Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal fat oxidative rate variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Healing Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With a Reportable Genetic Variant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of abstinence from alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choice Stepping Reaction Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Step Length Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alternate Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mRNA and protein expression in peripheral blood mononuclear cells/serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Unventilated Lung
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Accuracy of iThermonitor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With PCR-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Blood Concentration-time Curve Over the Last 24 Hours After Treatment Dose (AUC0-24h) of KAF156
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous pain or pain on biting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on percussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Linear changes of soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiogenesis at ischemic limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent Change in Kinesia HomeView Symptom Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SSI rate after pancreatic surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change in parents' reactions to children's emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in positive Involvement with children
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Parenting self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preparedness for Decision Making About Clinical Trial Participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12-month Incidence Rates of HIV and STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total Volume of All Crystalloid Given for Early Resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute Serious Bacterial Infections (SBI)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Infusions With Temporally Associated Adverse Events (TAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced One or More Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Potential Clinically Significant (PCS) Clinical Laboratory Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Meaningful Trends for Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Meaningful Trends in Electrocardiogram (ECG) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Basic fitness measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Depression Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuous glucose sensor data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Devices That Developed Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Days of Analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatine Kinase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation between IR-UWB radar and conventional monitor for HR and RR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference between IR-UWB radar and conventional monitor for HR and RR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal matching (%) between IR-UWB radar and conventional monitor for HR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection rate between IR-UWB radar and conventional monitor for HR and RR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events Frequency and Severity
Endpoint domain: Adverse events/effects
Primary endpoint: optimal Ce of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Basal Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak concentration (Cmax) after the first administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-264h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half time after the first administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Pathologic Stage =< pT2N0 at Prostatectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Medication error ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of pathologic diagnoses from deep biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes